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Introduction
Psychosis arises from difficulties establishing 
what is real and what is not, and is characterized 
by disordered thinking and speech, hallucina-
tions and delusions, so-called positive psychotic 
symptoms or experiences. A psychotic disorder 
constitutes more persistent and pervasive psy-
chotic symptoms, typically alongside a number 
of other deficits. One of the most severe psy-
chotic disorders is schizophrenia. It has long 
been acknowledged that there is a strong rela-
tionship between cigarette smoking and psy-
chotic disorders. More recently, smoking has 
also been found to be associated with psychotic 
experiences in the general population.1–3 Rates of 
cigarette smoking in individuals with psychotic 
disorders are 2–3 times greater than those with-
out.4 Moreover, tobacco smokers with psychotic 
disorders display patterns of heavy smoking,5 
severe nicotine dependence4 and are less likely to 
quit than nonsmokers.6 There is an increased risk 
of tobacco-related morbidity and excess mortal-
ity in this population,7 constituting a major con-
tributor to health inequalities.
The reasons underlying the smoking–psychosis 
association are unclear. A number of explanations 
have been proposed, which are not necessarily 
mutually exclusive:
1. Reverse causation: high rates and intensity of 
smoking in individuals with psychotic disor-
ders are secondary to the illness itself, whether 
through self-medication to alleviate symp-
toms or antipsychotic-induced side effects, 
to improve attention and working memory, 
or through a process of institutionalization.
2. Shared liability: psychotic disorders and cig-
arette smoking share some liability, likely 
genetic, and the high prevalence of tobacco 
smoking in this population is a manifesta-
tion of this common liability.
3. Confounding: tobacco smoking is associated 
with established risk factors for psychotic 
disorders, be they social (e.g. adversity) or 
biological (e.g. other drug use), which may 
be causally related to psychosis.
4. Smoking itself is causally related to psychosis: it 
is clear that smoking is neither a necessary 
nor a sufficient factor for the development 
of schizophrenia and related disorders. It 
can be inferred from temporality and dose-
dependence effects, however, that smoking 
could be a primary causative factor for 
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some cases of psychosis, or interact with 
other risk or precipitating factors.
In this paper we review the evidence for these 
hypotheses, using findings from the latest epide-
miological, neuroimaging, genetic and preclinical 
work.
Effects of nicotine on the brain
The main components of tobacco smoke are nic-
otine, which is an alkaloid found in tobacco 
leaves and the neurologically active agent respon-
sible for the addictive properties of cigarettes, 
and tars, the term given to the resinous, partially 
combusted particulate matter which includes 
polycyclic aromatic hydrocarbons, produced by 
the burning of tobacco. Inhalation of cigarette 
smoke distils nicotine from tobacco in the ciga-
rette. Nicotine attaches to tar droplets and is 
absorbed by tissues in the mouth, nose and pul-
monary alveoli, where it enters the pulmonary 
venous circulation.8 Nicotine rapidly crosses the 
blood–brain barrier, reaching the brain 10–20 s 
after inhalation.9
The nicotinic cholinergic receptor and 
neurotransmitter release
Nicotine binds to nicotinic acetylcholine recep-
tors (nAChRs). These are presynaptic receptors 
located throughout the brain, with the highest 
density in the thalamus, basal ganglia and cau-
date nucleus, followed by the frontal, parietal, 
temporal and occipital cortex, hippocampus and 
cerebellum.10 Neuronal nAChRs exist as multi-
ple subtypes of pentameric structures with 
unique combinations of at least 17 (α1–α10, 
β1–β4, γ, δ, ε) genetically distinct subunits; 
these have different distributions, functional 
properties and pharmacological profiles.11 
Nicotine demonstrates the highest affinity for 
nAChRs that contain α4 and β2 subunits; these 
are the most abundant nAChRs in the brain.12 
Nicotine binding opens an intrinsic ion channel 
in the receptor and allows the flow of cations 
(Na+, Ca2+, and K+) through the cell mem-
brane, activating voltage-gated calcium channels 
and leading to neurotransmitter release.8 
Nicotine is known to alter the release of virtually 
all major neurotransmitters, including dopa-
mine, acetylcholine, endogenous opioid pep-
tides, γ-aminobutyric acid (GABA), glutamate, 
noradrenaline and serotonin.13
Addictive and cognitive effects
Nicotine stimulates dopamine release in broad 
target areas throughout the brain. The addictive 
properties of nicotine appear to be primarily asso-
ciated with mesolimbic dopaminergic pathways; 
activation of nAChRs in the ventral tegmental 
area (VTA) results in the release of dopamine in 
the shell of the nucleus accumbens, which is 
important in the perception of pleasure and 
reward.14 Nicotine also increases glutamate and 
GABA transmission in the VTA.15 While nico-
tine-induced GABAergic transmission quickly 
desensitizes, the glutamatergic response does so 
to a lesser degree; there is therefore an overall 
shift where inhibitory GABAergic transmission is 
decreased and excitatory glutamatergic transmis-
sion is increased. This likely contributes to pro-
longed increases in dopamine release and the 
pattern of behavioural reinforcement seen in nic-
otine addiction. Interestingly, this mechanism has 
also been implicated in psychosis, with N-methyl-
D-aspartate (NMDA) receptor hypofunction on 
GABAergic interneurons resulting in reduced 
inhibition of pyramidal glutamate, with excess 
glutamate release leading to activation of dopa-
minergic neurons.16 The pro-cognitive properties 
of nicotine appear to be linked through the nico-
tine-induced release of dopamine in mesocortical 
pathways connecting the VTA with cortical 
regions, including the prefrontal cortex (PFC).14
Sensitivity to nicotine in the adolescent brain
Neural development is far from complete at birth, 
and continues into adolescence and early adult-
hood.17 This is a period of critical vulnerability for 
the initiation of tobacco smoking, with uptake 
during adolescence associated with severe nico-
tine dependence.18 There is variation in the rela-
tionship between nicotine exposure and neural 
structural characteristics across developmental 
epochs, and evidence suggests that nicotine may 
affect the trajectory of brain development, for 
example by modulating prefrontal cortical func-
tion.19 In animal models, frontostriatal circuitry is 
particularly vulnerable to nicotine exposure in 
adolescence,20 with ensuing cognitive deficits 
seen in later adulthood.21,22 Nicotine appears to 
have a role in influencing neuronal growth,23 and 
Nordman and colleagues show that stimulation of 
nicotinic receptors with nAChR agonists (such as 
nicotine) results in a decrease in axonal surface 
area.24 Moreover, chronic exposure to nicotine is 
associated with upregulation of nAChRs,25 and 
H Quigley and JH MacCabe
journals.sagepub.com/home/tpp 3
preclinical data suggest that the adolescent brain 
is more vulnerable to nicotine-induced increases 
in nAChR expression than the adult brain.26
Of note, it has been suggested that psychotic dis-
orders such as schizophrenia are neurodevelop-
mental in origin, with the emergence of prodromal 
symptoms typically occurring in adolescence and 
early adulthood. This has led to speculation that 
neurodevelopmental processes that take place 
during this period may be important in the expres-
sion of latent vulnerability for psychosis,27 and 
may be susceptible to the influence of psychoac-
tive substances such as nicotine.
In a recent study, Jobson and colleagues used a 
rodent model of adolescent neurodevelopment to 
show that exposure to nicotine during a critical 
period of adolescent neurodevelopment led to 
long-term behavioural, neuronal and molecular 
phenotypes consistent with mood and anxiety-
related disorders, including an alteration in neu-
ronal activity states in both dopaminergic neuronal 
populations in the mesolimbic VTA, and increased 
spontaneous neural activity in the PFC.28 This 
suggests a convergence of nicotine-induced neu-
roadaptation in the mesocorticolimbic system, 
leading to neuropsychiatric phenotypes which 
persist into adulthood, and has implications for 
the development of pharmacological interventions 
to prevent or reverse the long-term effects of nico-
tine exposure, as well as in identifying those who 
may be at increased risk from nicotine exposure 
during select periods of neurodevelopment.
The smoking–psychosis association: 
candidate hypotheses
Reverse causation
Until recently it was widely assumed that the 
smoking–psychosis association could be explained 
by reverse causation and that cigarette smoking 
was a consequence of the psychotic disorder itself. 
This could arise through: (1) a process of institu-
tionalization, whereby smoking habits are cultur-
ally transmitted via mental health settings; (2) 
due to psychotic individuals who smoke being 
less likely to give up due to more limited access to 
smoking cessation treatment and misguided atti-
tudes regarding the supposed psychological ben-
efits of smoking held by patients or mental health 
staff,29 (3) through boredom, apathy or reduced 
motivation as part of a deficit syndrome; or (4) as 
a deliberate attempt to alleviate the symptoms of 
the disorder or the adverse effects of antipsychotic 
drugs (often referred to as self-medication).
The self-medication hypothesis assumes that 
individuals with psychotic disorders smoke to 
allay clinical symptoms or treatment side effects.30 
Indeed, smokers with schizophrenia more com-
monly attribute their motivation to the calming, 
mood enhancing, and pro-cognitive effects of 
smoking than smoking controls.31 Nicotine has 
been shown to reduce sedating and other side 
effects of antipsychotic medication,32 as well as 
diminish negative psychotic symptoms33 and 
lessen distress. Use of nicotine prior to psychosis 
onset could be attributed to self-medication for 
anxiety in the prodromal phase of the illness.
Cigarette smoking in individuals with psychosis 
may be related to the type of antipsychotic. First 
generation antipsychotics (FGAs) such as halop-
eridol are associated with an increased risk of 
smoking.34 This may be explained by nicotine-
induced increases in dopaminergic activity, 
which compensate for the preferential D2 block-
ade produced by FGAs. Smoking has been associ-
ated with lower levels of antipsychotic-induced 
akathisia,35 possibly suggesting an increased pro-
pensity for smoking in individuals exhibiting 
akathisia, though this is not a universal finding.36 
Interestingly, studies have reported that clozapine 
might reduce smoking in patients with schizo-
phrenia.37–39 Clozapine binds more strongly to D4 
dopamine receptors than to D2 receptors and is 
associated with a lower incidence of extrapyrami-
dal side effects; akathisia is also a rare side effect.40 
Constituents of tobacco smoke can increase the 
metabolism of some antipsychotic drugs through 
induction of cytochrome P450 enzymes,41 thereby 
accelerating their metabolism.
Nicotine has been shown to improve cognitive 
deficits in individuals with psychosis, including 
working memory and attention,42–45 and in this 
context nAChRs have emerged as targets for the 
treatment of cognitive and negative symptoms.46,47 
It is postulated that nicotine compensates a hypo-
dopaminergic state in prefrontal brain regions, 
thought to underlie the negative symptoms and 
cognitive deficits seen in schizophrenia.48 Indeed, 
a recent study by Koukouli and colleagues showed 
that chronic nicotine administration reversed 
hypofrontality in mouse models of schizophre-
nia.49 There is a reduction in the density of α750 
and α4β2 nicotinic receptors51 in postmortem 
brain tissue of patients with schizophrenia, and 
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the degree of upregulation of α4β2 receptors in 
schizophrenia (for a given level of smoking) also 
appears to be impaired,52 further strengthening a 
compensatory role for tobacco smoking in schizo-
phrenia. Moreover, smoking may be implicated in 
improving a number of neurophysiological abnor-
malities associated with psychotic disorders, includ-
ing sensory gating deficits,53,54 pre-pulse inhibition,55 
and abnormal smooth pursuit eye movement.56
The fundamental principle of the self-medica-
tion hypothesis is that psychotic individuals seek 
out nicotine to alleviate the symptoms associ-
ated with the illness or side effects of treatments, 
that is smoking is initiated upon development of 
the illness, or initiation of antipsychotic medica-
tion. Evidence for this, however, is scarce.57 
Furthermore, symptoms of psychosis do not 
appear to be exacerbated by smoking cessation.58 
Not all studies have found an improvement in 
cognition with nicotine use in individuals with 
psychotic disorders,59–61 and many of those that 
did failed to match groups on smoking severity, 
thus the greater nicotine effects in individuals 
with psychosis may reflect more pronounced 
withdrawal-induced deficits, as a result of heavier 
smoking.61 A review conducted by Prochaska and 
colleagues exposed that the tobacco industry 
monitored or directly funded research promoting 
the idea that individuals with schizophrenia need 
tobacco to self-medicate, and that they are less 
susceptible to the harms of tobacco smoking.62 
Such revelations have stimulated further empiri-
cal research and novel and alternative hypotheses 
to the notion of self-medication.63,64
Shared genetic liability
Shared genetic liability to both smoking and psy-
chosis has been suggested based on findings from 
discordant twin and sibling studies of schizophre-
nia.65,66 A Swedish study by Kendler and col-
leagues found, in a co-relative analysis, that heavy 
smokers in discordant monozygotic twin pairs 
were approximately 1.7-times more likely to 
develop psychosis compared with the nonsmok-
ing twin, however, there was only a modest 
decrease in the hazard ratio when comparing full 
siblings to half-siblings, cousins or the general 
population,67 suggesting that genetic factors can-
not fully explain the relationship between smok-
ing and risk of psychosis.
Large scale genome-wide association studies 
(GWASs) have identified risk genes for many 
complex human diseases and traits, including 
schizophrenia68 and smoking behaviour pheno-
types,69 which provide an opportunity to examine 
the genetic relationship between correlated traits, 
as well as identify shared risk genes. The 
Schizophrenia Working Group of the Psychiatric 
Genomics Consortium identified 108 genome-
wide significant loci associated with an increased 
risk of schizophrenia, and one of these is located 
in a cluster of genes, CHRNA5-A3-B5 which 
code for the α5-α3-β4 nicotinic receptor subunit, 
the strongest genetic contributor to nicotine 
dependence.69–71 There are three further genetic 
studies that have also cast nicotine dependence as 
a phenotype that shares genetic liability with 
schizophrenia.72–74 For example, Reginsson and 
colleagues use polygenic risk scores for schizo-
phrenia to predict smoking and nicotine depend-
ence in an Icelandic sample, suggesting shared 
genetic aetiology, and show that as smoking rates 
decline, genetic risk appears to gain importance 
as a determinant of smoking behaviour.74 A 
shared genetic architecture could suggest biologi-
cal pleiotropy, in which a single locus affects mul-
tiple traits; however, alternate explanations are 
possible, involving mediated pleiotropy wherein 
one phenotype is itself causally influenced by the 
second phenotype, consistent with causal or 
reverse-causal effects.75
Causality can be studied in observational epide-
miological studies using Mendelian randomiza-
tion (MR), whereby randomly assorted genetic 
variants that are associated with an environmental 
exposure are used as proxy measures for the expo-
sure itself. Subject to certain assumptions, MR 
has the potential to overcome many of the biases 
that impact the validity of traditional approaches 
such as confounding and reverse causation.76 A 
MR study by Wium-Andersen and colleagues 
found that a single nucleotide polymorphism 
(SNP) in the CHRNA3 gene associated with 
smoking intensity and the likelihood of receiving 
a prescription for antipsychotic medication (con-
sidered a proxy for risk of psychotic illness), sug-
gesting that smoking could have a causal influence 
on the development of psychosis.77 Two-sample 
MR has recently been developed, in which data 
on the gene-risk factor and gene-outcome associ-
ations are taken from different data sources to 
conduct MR analyses.78 Using this technique, 
Gage and colleagues combined SNPs associated 
with smoking initiation (from the Tobacco and 
Genetics Consortium69) and schizophrenia (from 
the Psychiatric Genetics Consortium68) and show 
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little evidence of a causal association between 
smoking initiation and schizophrenia in either 
direction,79 which supports a possible pleiotropic 
effect. However, the authors emphasize that this 
does not rule out a causal effect of smoking on 
schizophrenia related to heavier, lifetime expo-
sure. In a recent study, Wootton and colleagues 
describe the development of a novel genetic 
instrument for lifetime exposure that can be used 
in two-sample MR without the need to stratify by 
smoking status, and using this instrument the 
authors report evidence that the association 
between smoking and schizophrenia is due, at 
least in part, to a causal effect of smoking.80
Confounder, mediator, or a special relationship 
with cannabis?
To further complicate matters, tobacco smoking 
is associated with established environmental risk 
factors for psychosis such as adversity and child-
hood trauma,81 and illicit substance use.82
Cannabis is the most commonly studied illicit 
substance and its association with psychosis is 
widely accepted to be at least partly causal in 
nature, and related to its potency.83 Cannabis and 
tobacco smoking are highly correlated with one 
another,84 and while many cigarette smokers do 
not use cannabis, a high proportion of cannabis 
users smoke tobacco,85 either concurrently as cig-
arettes (co-use) or as a component of cannabis 
joints (simultaneous use).
The relationship between these two substances is 
complex and challenging to disentangle. The 
‘gateway’ hypothesis suggests that tobacco smok-
ing acts as a gateway to the use of cannabis,86 
however, there is evidence for the ‘reverse gate-
way’, whereby cannabis smoking paves the way 
for tobacco initiation,87 as well as evidence impli-
cating genetic factors associated with the use of 
both drugs.84 Tobacco smoking increases the 
amount of tetrahydrocannabinol inhaled per 
gram,88 thus enhancing the subjective effect of 
cannabis. In a naturalistic study of cannabis and 
tobacco co-users, tobacco smoking has been 
shown to mediate the relationship between can-
nabis use and cannabis dependence, even when 
controlling for psychological and demographic 
correlates that could explain this relationship, 
perhaps due to the more addictive properties of 
nicotine.89 Preliminary experimental evidence 
also suggests that tobacco may offset the effects of 
cannabis on delayed verbal recall and working 
memory.90 Co-use of tobacco and cannabis also 
leads to poorer psychosocial, cessation and physi-
cal health outcomes.91,92 Thus, it is plausible that 
tobacco smoking might directly perpetuate can-
nabis dependence and relapse in co-dependent 
users, in this way mediating the risk of developing 
psychosis. Evidence also exists to suggest a pos-
sible synergistic effect whereby the combination 
of tobacco and cannabis gives rise to psychotic 
symptoms.2 There might be implications for clini-
cal practice here, given the lack of empirical 
research guiding treatments for simultaneous and 
co-use of tobacco and cannabis,84,93 particularly 
in those with psychotic disorders.
Recent lines of evidence suggest that the endo-
cannabinoid system, which is implicated in a host 
of physiological processes and the system through 
which cannabis exerts its psychological and physi-
cal effects, may play a role in the rewarding and 
reinforcing effects of nicotine.94 For example, 
genetically deleting or pharmacologically block-
ing CB1 cannabinoid receptors reduces or elimi-
nates many of the behavioural and neurobiological 
effects of nicotine that are responsible for its 
addictive potential.95 There is current interest in 
the endocannabinoid system as a therapeutic tar-
get for nicotine addiction,96 as well as in the treat-
ment of psychosis.97
Causal effect
More recently, attention has been directed towards 
the possibility that tobacco smoking might be 
causally related to risk of psychosis. There are two 
meta-analyses that have reported strong associa-
tions between tobacco smoking and an increased 
risk of having a psychotic disorder estimating odds 
ratios in smokers versus nonsmokers of 6.04 [95% 
confidence interval (CI) 3.03–12.02]57 and 3.22 
(95% CI 1.63–6.33).98 The latter study showed 
that daily smokers experienced their first psy-
chotic episode at an earlier age than nonsmokers 
(weighted mean difference −1.04 years, 95% CI 
−1.82 to −0.26), and for prospective studies, cal-
culated an overall relative risk of new psychotic 
disorders in daily smokers versus nonsmokers of 
2.18 (95% CI 1.23–3.85). Moreover, those with 
psychosis started smoking at a nonsignificantly 
earlier age than did healthy controls (−0.44 years, 
95% CI −1.21 to 0.34). These meta-analyses were 
not able to adjust for substances other than 
tobacco (e.g. cannabis use) as very few studies 
measured or controlled for these variables objec-
tively; they are further limited by comparatively 
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small numbers of longitudinal prospective studies. 
Of note, early initiation of daily smoking is also 
associated with greater risk of later developing a 
psychotic illness, consistent with the hypothesis 
that exposure during a critical period of brain 
development may be specifically associated with 
psychosis risk.63,99
The Bradford Hill criteria can be useful in estab-
lishing epidemiologic evidence of a causal rela-
tionship between a presumed cause and an 
observed effect, and constitute the strength, con-
sistency, specificity, temporality, biological gradi-
ent, plausibility, coherence, experiment, and 
analogy of an association.100 In relation to strength, 
the association reported in prospective studies 
undertaken in the general population identifies a 
modest increase in relative risk. Moreover, the 
association has persisted after adjustment for 
smoking onset during a prodromal period, and 
other risk factors such as socioeconomic status, 
other drug use, baseline psychotic experiences and 
parental psychosis and drug use.63,67 The findings 
appear to be consistent between different popula-
tions.101,102 With the exception of one sample, 
wherein cigarette smoking reduced risk of later 
developing schizophrenia,103 cigarette smoking 
typically predates psychosis onset, thereby satisfy-
ing temporality criteria, and prospective studies 
demonstrate a dose–response effect, suggesting 
that a biological gradient exists.67,104,105 Further, 
daily smoking appears to have a greater effect on 
the positive symptoms of psychosis,106 and there is 
evidence that schizophrenia with comorbid nico-
tine dependence is more severe and has worse 
clinical and functional outcomes.104,107,108 
Smoking affects a number of disease processes, 
therefore limiting the applicability of the specific-
ity criterion, while experimental animal models of 
psychosis do not exist.
If cigarette smoking is causally related to psycho-
sis, we must consider how this might plausibly fit 
with our current understanding of the neurobiol-
ogy of psychosis, which implicates excess subcor-
tical dopamine synthesis and release.109 Nicotine 
appears to increase dopamine release directly and 
to a similar extent as other misused substances, as 
measured in vivo by positron emission tomogra-
phy (PET) in the dorsalventral striatum and basal 
ganglia.110,111 Bloomfield and colleagues, how-
ever, show that moderate smoking does not 
appear to be associated with marked effects on 
striatal dopamine synthesis capacity, in contrast 
with previous findings of elevated dopamine 
synthesis capacity in heavy smokers.112 Nicotine 
alters the release of almost all major neurotrans-
mitters, many of which have been implicated in 
the pathogenesis of psychotic symptoms.13 There 
is also an inverse relationship between smoking 
and risk of Parkinson’s disease,113 a dopamine 
deficiency disorder. Work in animal models 
shows that nicotine exposure might increase D2 
high-affinity receptors114 thus supporting a role 
for nicotine in the induction of supersensitive D2 
receptors, which has been posited as an underly-
ing mechanism for a number of schizophrenia risk 
factors, and as a common pathway for symptoms 
of psychosis.115
Thus far, we have primarily focused on the rela-
tionship between nicotine and dopamine. A num-
ber of other factors, however, have relevance in 
terms of their relationship with both cigarette 
smoking and the pathoaetiology of psychosis. 
First, much attention has recently been directed 
towards inflammation and the neural diathesis-
stress hypothesis of schizophrenia,116 and cigarette 
smoking is highly associated with both the release 
and inhibition of proinflammatory and anti-
inflammatory mediators.117 Indeed, inflammatory 
processes underlie a number of the physical health 
consequences of smoking, and preclinical studies 
show that peripheral inflammation can induce 
neuroinflammation.118 Inflammatory cytokines 
may also modulate dopaminergic and glutamater-
gic neurotransmission directly.119,120 Second, con-
stituents of cigarette smoke have significant effects 
on the endocrine system, for example altering pro-
duction and metabolism of estradiol,121 which is 
thought to contribute to the sex differences in 
schizophrenia incidence,122 as well as cortisol,123 
which has also been implicated in psychosis.124 
Finally, epigenetic processes may mediate the 
relationship between genetic risk burden, environ-
mental exposure, and phenotype, and increasing 
emphasis has been placed on the potential role of 
epigenetic dysfunction in the aetiology of psycho-
sis.125 Smoking is strongly associated with DNA 
methylation in a distinct set of loci,126 thus inves-
tigation of the tobacco epigenetic signature in 
individuals with psychosis may provide insight 
into mechanisms by which tobacco smoking and 
psychosis are associated.
There is increasing acceptance that schizophrenia 
is not a homogenous disorder; instead, it is likely 
that subtypes of schizophrenia exist, reflecting 
distinct neurobiological aetiologies. As the risk 
that smoking confers in the development of 
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cancer varies as the subtype of cancer becomes 
more specific, so too might parallels exist with 
subtypes of schizophrenia.
Discussion
In this review we have compared the evidence for 
four possible explanations for the relationship 
between smoking and psychosis. The elevated 
smoking rates found in those with psychosis led to 
the supposition that these individuals smoke to 
self-medicate, and a self-medication hypothesis 
put forward almost 40 years ago remained the 
default explanation for the association between 
smoking and psychosis. However, over recent 
years, studies have exposed that self-medication 
and reverse causation cannot fully explain the 
association. The jury is out on whether tobacco 
might be causally related to the risk for psychosis, 
or whether the association manifests through a 
shared genetic vulnerability, or is  confounded by 
use of illicit substances or other social factors. Of 
course, if smoking is a causal risk factor for psycho-
sis, this does not preclude the  possibility that 
smoking is also used as a form of self-medication, 
and indeed the dopaminergic effects of nicotine on 
the mesocorticolimbic pathway might support this.
Of growing relevance is the increasing use and 
popularity of nicotine-containing products, par-
ticularly electronic cigarettes (which typically 
contain high levels of nicotine). By encouraging 
the use of such products as part of smoking cessa-
tion programmes, clinicians may be inadvertently 
increasing psychotic symptoms. To our knowl-
edge this has not been studied directly; however, 
Munafo and colleagues reported a modest asso-
ciation with using ‘snus’, a form of buccally 
absorbed moist tobacco, and risk for nonaffective 
psychosis in a large Swedish registry data set.127 
These results suggest that any causal mediator is 
present in unburned tobacco products, and 
although perhaps the most plausible and widely 
studied culprit is nicotine, there are other possible 
mechanisms such as inhibition of monoamine 
oxidase, which is involved in the degradation of 
dopamine.128 It might be that different constitu-
ents account for different neurobiological effects; 
some might improve symptoms, while others 
might exacerbate them. Determining which con-
stituents are responsible may have important 
public health implications.
Nevertheless, the dramatic declines in cigarette 
smoking seen in the general population have not 
been reflected in individuals with psychotic dis-
orders,129 and there is also stark evidence that 
the mortality gap is widening.130 Establishing 
smoke-free inpatient psychiatric units is a goal 
that hospitals and policymakers are increasingly 
supporting, however the impact on long-term 
patterns of smoking in this population remains 
to be elucidated. While science continues the 
challenging task of unravelling this complex rela-
tionship, every effort should be made to imple-
ment change in smoking behaviours in this 
population, with initiation of counselling and 
treatment for nicotine dependence alongside 
treatment for the primary psychotic disorder.
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